2023-08-15 16:20:35 ET
More on Reata Pharmaceuticals
- Biogen's Bold $7.3B Acquisition Of Reata: Analyzing The Impact On Investors
- Reata: FDA Approval Of SKYCLARYS Isn't Only Driver Moving Forward
- Reata Pharmaceuticals: 'Buy' Following Skyclarys Delay And Bardoxolone Discontinuation (Rating Upgrade)
- Biggest stock movers today: Reata Pharmaceuticals, Enphase Energy, Roku and more
- TD Cowen starts Reata at outperform, cites sales potential of ataxia drug
- Reata gains after FDA nod for Skyclarys marketing supplement
- Seeking Alpha’s Quant Rating on Reata Pharmaceuticals
- Earnings data for Reata Pharmaceuticals
For further details see:
Sanofi was mystery bidder in Reata Pharma bidding war - report